MD III - Akari Therapeutics Executive Officer
| AKTX Stock | USD 1.03 0.27 20.77% |
Executive
MD III is Executive Officer of Akari Therapeutics PLC
| Age | 71 |
| Address | 22 Boston Wharf Road, Boston, MA, United States, 02210 |
| Phone | 929 274 7510 |
| Web | https://www.akaritx.com |
Akari Therapeutics Management Efficiency
The company has return on total asset (ROA) of (1.7283) % which means that it has lost $1.7283 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (12.8143) %, meaning that it created substantial loss on money invested by shareholders. Akari Therapeutics' management efficiency ratios could be used to measure how well Akari Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Akari Therapeutics' Return On Capital Employed is fairly stable compared to the past year. Return On Equity is likely to rise to 45.89 in 2024, whereas Return On Tangible Assets are likely to drop (2.42) in 2024. At this time, Akari Therapeutics' Other Current Assets are fairly stable compared to the past year. Tangible Asset Value is likely to rise to about 5.9 M in 2024, whereas Total Assets are likely to drop slightly above 4.1 M in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Stephen McAndrew | Sonnet Biotherapeutics Holdings | 70 | |
| Patricia Hirano | Soleno Therapeutics | 58 | |
| MD FACC | Capricor Therapeutics | 68 | |
| Michael MD | Soleno Therapeutics | 50 | |
| Jesse Schumaker | Soleno Therapeutics | N/A | |
| James Stanker | Processa Pharmaceuticals | 66 | |
| Gael Hedou | Sonnet Biotherapeutics Holdings | 52 | |
| Deborah Ascheim | Capricor Therapeutics | 59 | |
| Steven MD | Processa Pharmaceuticals | N/A | |
| Bryan Kadotani | Armata Pharmaceuticals | N/A | |
| Pierre Kyme | Armata Pharmaceuticals | N/A | |
| David JD | Pulmatrix | 66 | |
| PharmD MBA | Soleno Therapeutics | N/A | |
| Peter Hubbard | Armata Pharmaceuticals | N/A | |
| Patricia MPH | Soleno Therapeutics | 58 | |
| Kristi Elliott | Capricor Therapeutics | N/A | |
| David House | Armata Pharmaceuticals | N/A | |
| JD Esq | Processa Pharmaceuticals | 50 | |
| Dr MBA | Soleno Therapeutics | N/A | |
| MPH MD | Salarius Pharmaceuticals | N/A | |
| Lauren Budesheim | Soleno Therapeutics | N/A | |
Management Performance
| Return On Equity | -12.81 | ||||
| Return On Asset | -1.73 |
Akari Therapeutics PLC Leadership Team
Elected by the shareholders, the Akari Therapeutics' board of directors comprises two types of representatives: Akari Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Akari. The board's role is to monitor Akari Therapeutics' management team and ensure that shareholders' interests are well served. Akari Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Akari Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Torsten Hombeck, Chief Officer | ||
| Annie Mack, Financial Controller | ||
| MD III, Executive Officer | ||
| Samir MD, CEO President | ||
| Ray MD, Ex Chairman | ||
| BethAnne Lang, Senior Affairs | ||
| Rachelle Jacques, CEO President | ||
| Wendy CPA, Interim Officer | ||
| Miles Nunn, Chief Officer | ||
| Melissa BradfordKlug, Chief Officer |
Akari Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Akari Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -12.81 | ||||
| Return On Asset | -1.73 | ||||
| Current Valuation | 24.26 M | ||||
| Shares Outstanding | 20.65 M | ||||
| Shares Owned By Insiders | 11.90 % | ||||
| Shares Owned By Institutions | 0.50 % | ||||
| Number Of Shares Shorted | 21.29 K | ||||
| Price To Earning | (2.15) X | ||||
| Price To Book | 3.07 X | ||||
| EBITDA | (16.8 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Akari Stock Analysis
When running Akari Therapeutics' price analysis, check to measure Akari Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Akari Therapeutics is operating at the current time. Most of Akari Therapeutics' value examination focuses on studying past and present price action to predict the probability of Akari Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Akari Therapeutics' price. Additionally, you may evaluate how the addition of Akari Therapeutics to your portfolios can decrease your overall portfolio volatility.